New hope for HAE: Long-Term trial of navenibart launches
NCT ID NCT07204938
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests the long-term safety and effectiveness of navenibart, an injectable drug, in 145 adults and teens with hereditary angioedema (HAE) who were in a previous study. The trial has two parts: first, everyone gets a fixed dose; then, some may switch to a personalized dose based on their needs. Researchers will track side effects and how well the drug prevents swelling attacks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
navenibart (also called STAR-0215), given as a shot under the skin
What this could lead to
If successful, this could provide a long-term treatment option to prevent swelling attacks in people with hereditary angioedema, potentially improving quality of life.
What could go wrong
This is an extension study, so participants already know the drug is safe enough to continue. However, long-term side effects are still being tracked, and the personalized dosing part is new, so its benefits are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 1
Walnut Creek, California, 94598, United States
-
Site 10
Hong Kong, Hong Kong
-
Site 11
Cape Town, South Africa
-
Site 12
Bristol, BS10 5N, United Kingdom
-
Site 13
London, E1 2ES, United Kingdom
-
Site 14
Frimley, GU16 7UJ, United Kingdom
-
Site 14
Plymouth, PL6 8HD, United Kingdom
-
Site 15
Hampstead, NW3 2QG, United Kingdom
-
Site 16
Rzeszów, 35-051, Poland
-
Site 17
Amsterdam, Netherlands
-
Site 18
Skopje, 1000, North Macedonia
-
Site 19
Colorado Springs, Colorado, 80907, United States
-
Site 2
Scottsdale, Arizona, 85251, United States
-
Site 20
Sofia, 1680, Bulgaria
-
Site 21
Wheaton, Maryland, 20902, United States
-
Site 22
Santo André, 09060870, Brazil
-
Site 23
Edmonton, AB T6G 2B7, Canada
-
Site 24
Petah Tikva, 4920235, Israel
-
Site 25
Frankfurt, D-60590, Germany
-
Site 26
Valencia, 46026, Spain
-
Site 27
Fukuoka, 830-0011, Japan
-
Site 3
Little Rock, Arkansas, 72205, United States
-
Site 4
Santa Monica, California, 90404, United States
-
Site 5
Centennial, Colorado, 80112, United States
-
Site 6
Cincinnati, Ohio, 45236, United States
-
Site 7
San Diego, California, 92122, United States
-
Site 8
Cambridge, CB2 0QQ, United Kingdom
-
Site 9
Hershey, Pennsylvania, 17033, United States